Бiомаркери сепсису у дiтей

В. І. Снiсарь

Анотація


Представлено данi щодо основних дiагностичних та прогностичних бiомаркерiв наявностi iнфекцiї у дiтей: С-реактивного бiлка (C-РБ), швидкостi осiдання еритроцитiв (ШОЕ), прокальцитонiну (ПКТ), iнтерлейкiну-6 (IЛ-6), iнтерлейкiну-1 антагонiста рецептора (IЛ–1ra), iнтерлейкiну-8 (IЛ-8) , фактора некрозу пухлини (ФНП), критичного рецептора експресiї мiєлоїдних клiтин (sTREM)-1, бiлкiв високої мобiльної групи (HMGB1). Незважаючи на численнi науково – дослiдницькi роботи з вивчення бiомаркерiв сепсису, їх використання в клiнiчнiй педiатричнiй практицi ще обмежене. Останнiм часом велику увагу придiляють вивченню дiагностичної цiнностi бiомаркерiв, що пов'язано з високою смертнiстю новонароджених i дiтей вiд сепсису.

Ключові слова


бiомаркери; сепсис; дiти

Повний текст:

PDF (Русский)

Посилання


Bone RC (1996) Newton, sepsis, SIRS, and CARS. Crit Care Med; 24: 1125-8.

Kutko MC, Calarco MP, Flaherty MB, et al. (2003) Mortality rates in pediatric septic shock with and without multiple organ system failure. Pediatr Crit Care Med; 4(3): 333–7.

Odetola FO, Gebremariam A, Freed GL (2007) Patient and hospital correlates of clinical outcomes and resource utilization in severe pediatric sepsis. Pediatrics; 119(3): 487–94.

Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther; 69(3): 89–95.

Meem M, Modak JK, Mortuza R, et al. (2011) Biomarkers for diagnosis of neonatal infections: A systematic analysis of their potential as a point-of-care diagnostics. J Glob Health;1(2):201–9.

Schelonka RL, Infante AJ (1998) Neonatal immunology. Semin Perinatol; 22(1): 2–14.

Allen UD (2005) Factors influencing predisposition to sepsis in children with cancers and acquired immunodeficiencies unrelated to human immunodeficiency virus infection. Pediatr Crit Care Med; 6(Suppl 3): S80-6.

Roongsritong C, Warraich I, Bradley C (2004) Common causes of troponin elevations in the absence of acute myocardial infarction: incidence and clinical significance. Chest; 125(5): 1877-84.

Enguix A, Rey C, Concha A, et al. (2001) Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically in neonates and children. Intensive Care Med; 27(1): 211–5.

Kuster H, Weis s M, Willeitner AE, et al. (1998) Interleukin–1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation. Lancet; 352(9136):1271–7.

Li JJ, Zhang T. (2013) [Diagnostic value of serum СRP and procalcitonin levels in children with bloodstream infection-associated sepsis and septic infection at other sites]. Zhongguo Dang Dai Er Ke Za Zhi;15(3):212–5.

Magudumana MO, Ballot DE, Cooper PA, et al. (2000) Serial interleukin 6 measurements in the early diagnosis of neonatal sepsis. J Trop Pediatr; 46(5): 267–71.

Sanders S, Barnett A, Correa-Velez I et al. (2008) Systematic review of the diagnostic accuracy of C-reactive protein to detect bacterial infection in nonhospitalized infants and children with fever. J Pediatr; 153(4): 570-4.

Jeschke MG, Finnerty CC, Kulp GA, et al. (2013) Can we use C-reactive protein levels to predict severe infection or sepsis in severely burned patients? Int J Burns Trauma;3(3):137-43.

Barati M, Alinejad F, Bahar MA, et al. (2008) Comparison of WBC, ESR, CRP and PCT serum levels in septic and non-septic burn cases. Burns; 34(6): 770-4.

Aydin B, Dilli D, Zenciro?lu A, et al. (2013) Comparison of a rapid bed-side test with a central laboratory analysis for C-reactive protein in newborn infants with suspicion of sepsis. Clin Lab; 59(9–10):1045–51.

Dornbusch HJ, Strenger V, Sovinz P, et al. (2008) Non-infectious causes of elevated procalcitonin and C-reactive protein serum levels in pediatric patients with hematologic and oncologic disorders. Support Care Cancer; 16(9): 1035-40.

Sherwin C, Broadbent R, Young S, et al. (2008) Utility of interleukin–12 and interleukin–10 in comparison with other cytokines and acute-phase reactants in the diagnosis of neonatal sepsis. Am J Perinatol; 25(10): 629–36.

Simon L, Saint-Louis P, Amre DK, et al. (2008) Procalcitonin and C-reactive protein as markers of bacterial infection in critically IL-l children at onset of systemic inflammatory response syndrome. Pediatr Crit Care Med; 9(4): 407–13.

Boonkasidecha S, Panburana J, Chansakulporn S, et al. (2013) An optimal cut-off point of serum C-reactive protein in prediction of neonatal sepsis. J Med Assoc Thai.; 96, Suppl 1:S65–70.

Pulliam PN, Attia MW, Cronan KM (2001) C-reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection. Pediatrics; 108(6): 1275–9.

Lacour AG, Gervaix A, Zamora SA, et al. (2001) Procalcitonin, IL-6, IL-8, IL–1 receptor antagonist and C-reactive protein as identificators of serious bacterial infections in children with fever without localising signs. Eur J Pediatr; 160(2): 95–100.

Berger RM, Berger MY, van Steensel-Moll HA, et al. (1996) A predictive model to estimate the risk of serious bacterial infections in febrile infants. Eur J Pediatr; 155(6): 468–73.

Sakha K, Husseini MB, Seyyedsadri N (2008) The role of the procalcitonin in diagnosis of neonatal sepsis and correlation between procalcitonin and C-reactive protein in these patients. Pak J Biol Sci; 11(14): 1785–90.

Meisner M, Rauschmayer C, Schmidt J, et al. (2002) Early increase of procalcitonin after cardiovascular surgery in patients with postoperative complications. Intensive Care Med; 28(8): 1094–102.

Bhattacharyya K, Bandyopadhyay M, Karmakar BC et al. (2012) A study on blood culture positivity and C-reactive protein variability in neonatal septicaemia at neonatal intensive care unit of a tertiary care hospital. J Indian Med Assoc;110(12):920–1, 925.

Hengst JM (2003) The role of C-reactive protein in the evaluation and management of infants with suspected sepsis. Adv Neonatal Care; 3(1): 3–13.

Parida SN, Verma IC, Singh MB, Thomas S (1980) Evaluation of micro erythrocyte sedimentation rate in the diagnosis of neonatal sepsis. Ind J Pediatr; 47(388): 381-4.

Greer JP, Foerrster J, Rodgers G, et al. (2008) Wintrobe's Clinical Hematology. 12th ed. Philadelphia: Lippincott, Williams, and Wilkins.

Meisner M, Adina H, Schmidt J (2006) Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. Crit Care; 10(1): R1.

Dubos F, Korczowski B, Aygun DA, et al. (2008) Serum procalcitonin level and other biological markers to distinguish between bacterial and aseptic meningitis in children: a European multicenter case cohort study. Arch Pediatr Adolesc Med; 162(12): 1157-63.

Tseng JS, Chan MC, Hsu JY, et al. (2008) Procalcitonin is a valuable prognostic marker in ARDS caused by community-acquired pneumonia. Respirology; 13(4): 505–9.

Fioretto JR, Martin JG, Kurokawa CS, et al. (2008) Interleukin-6 and procalcitonin in children with sepsis and septic shock. Cytokine; 43(2): 160-4.

Andreola B, Bressan S, Callegaro S, et al. (2007) Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department. Pediatr Infect Dis J; 26(8): 672–7.

Adib M, Bakhshiani Z, Navaei F, et al. (2012) Procalcitonin: a reliable marker for the diagnosis of neonatal sepsis. Iran J Basic Med Sci;15(2): 777-82.

Ucar B, Yildiz B, Aksit MA, et al. (2008) Serum amyloid A, procalcitonin, tumor necrosis factor-alpha, and interleukin–1beta levels in neonatal late-onset sepsis. Mediators Inflam: 737141.

Hammer S, Meisner F, Dirschedl P, et al. (2000) Procalcitonin for differential diagnosis of graft rejection and infection in patients with heart and/or lung grafts. Intensive Care Med; 26 (Suppl 2): S182-6.

Liu SF, Yuan GP, Yang J, et al. (2012) [Procalcitonin as a predictor of trauma severity and post-traumatic sepsis in children]. Sichuan Da Xue Xue Bao Yi Xue Ban; 43(5): 706–10.

Prashant A, Vishwanath P, Kulkarni P, et al. (2013) Comparative assessment of cytokines and other inflammatory markers for the early diagnosis of neonatal sepsis-a case control study. PloS One; 8(7):e68426.

Kitanovski L, Jazbec J, Hojker S, Derganc M. (2014) Diagnostic accuracy of lipopolysaccharide-binding protein for predicting bacteremia/clinical sepsis in children with febrile neutropenia: comparison with interleukin-6, procalcitonin, and C-reactive protein. Support Care Cancer; 22(1): 269–77.

Lacour AG, Gervaix A, Zamora SA, et al. (2001) Procalcitonin, IL-6, IL -8, IL–1 receptor antagonist and C-reactive protein as identificators of serious bacterial infections in children with fever without localising signs. Eur J Pediatr; 160(2):95–100.

Strait RT, Kelly KJ, Kurup VP (1999) Tumor necrosis factor-alpha, interleukin–1 beta, and interleukin-6 levels in febrile, young children with and without occult bacteremia. Pediatrics;104(6):1321-6.

Diepold M, Noellke P, Duffner U, et al. (2008) Performance of Interleukin-6 and Interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk. BMC Infect Dis; 8: 28.

Fischer JE, Benn A, Harbarth S, Nadal D, Fanconi S (2002) Diagnostic accuracy of G-CSF, IL-8, and IL–1ra in critically children with suspected infection. Intensive Care Med; 28(9): 1324–31.

Blackwell TS, Christman JW (1996) Sepsis and cytokines: current status. Br J Anaesth; 77(1): 110–7.

Lehrnbecher T, Venzon D, de Haas M, et al. (1999) Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis; 29(2): 414–9.

Vermont CL, Hazelzet JA, de Kleijn ED, et al. (2006) CC and CXC chemokine levels in children with meningococcal sepsis accurately predict mortality and disease severity. Crit Care; 10(1): R33.

Carrol ED, Thomson AP, Jones AP, et al. (2005) A predominantly anti-inflammatory cytokine profile is associated with disease severity in meningococcal sepsis. Intensive Care Med; 31(10): 1415–9.

Franz AR, Bauer K, Schalk A, et al. (2004) Measurement of interleukin 8 in combination with C-reactive protein reduced unnecessary antibiotic therapy in newborn infants: a multicenter, randomized, controlled trial. Pediatrics; 114(1): 1-8.

Umlauf VN, Dreschers S, Orlikowsky TW (2013) Flow cytometry in the detection of neonatal sepsis. Int J Pediatr;2013: 763191.

Sugitharini V, Prema A, Berla Thangam E (2013) Inflammatory mediators of systemic inflammation in neonatal sepsis. Inflamm Res; 62(12): 1025–34.

Santolaya ME, Alvarez AM, Avil?s CL, et al. (2013) Prospective validation of a risk prediction model for severe sepsis in children with cancer and high risk fever and neutropenia. Pediatr Infect Dis J.

Zidi I, Mestiri S, Bartegi A, Amor NB (2010) TNF-alpha and its inhibitors in cancer. Med Oncol; 27(2): 185–98.

Njau F, Wittkop U, Rohde M, et al. (2009) In vitro neutralization of tumor necrosis factor-alpha during Chlamydia pneumoniae infection impairs dendritic cells maturation/function and increases chlamydial progeny. FEMS Immunol Med Microbiol; 55(2): 215–25.

Silveira RC, Procianoy RS (1999) Evaluation of interleukin-6, tumour necrosis factor-alpha and interleukin–1beta for early diagnosis of neonatal sepsis. Acta Paediatr; 88(6): 647–50.

Dollner H, Vatten L, Austgulen R (2001) Early diagnostic markers for neonatal sepsis: comparing C-reactive protein, interleukin-6, soluble tumour necrosis factor receptors and soluble adhesion molecules. J Clin Epidemiol; 54(12): 1251–7.

Doellner H, Arntzen KJ, Haereid PE, et al. (1998) Increased serum concentrations of soluble tumor necrosis factor receptors p55 and p75 in early onset neonatal sepsis. Early Hum Dev; 52(3): 251-61.

Kumar S, Rizvi M (2010) Serum tumor necrosis factor alpha and C-reactive protein in pediatric patients with sepsis and its correlation with microbiologic findings. Indian J Pathol Microbiol;53(3): 494–7.

Santana RC, Garcia-Munoz F, Reyes D, et al. (2003) Role of cytokines (interleukin–1beta, 6, 8, tumour necrosis factor-alpha, and soluble receptor of interleukin–2) and C- reactive protein in the diagnosis of neonatal sepsis. Acta Paediatr; 92(2): 221–7.

Phumeetham S, Chat-Uthai N, Manavathongchai M, Viprakasit V (2012) Genetic association study of tumor necrosis factor-alpha with sepsis and septic shock in Thai pediatric patients. J Pediatr (Rio J);88(5):417–22.

Ventetuolo CE, Levy MM, Ventetuolo CE, Levy MM (2008) Biomarkers: diagnosis and risk assessment in sepsis. Clin Chest Med; 29(4): 591-603.

Routsi C, Giamarellos-Bourboulis EJ, Antonopoulou A, et al. (2005) Does soluble triggering receptor expressed on myeloid cells–1 play any role in the pathogenesis of septic shock? Clin Exp Immunol; 142(1): 62–7.

Gibot S, Cravoisy A, Kolopp-Sarda MN, et al. (2005) Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)–1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med; 33(4): 792-6.

Dimopoulou I, Orfanos SE, Pelekanou A, et al. (2009) Serum of patients with septic shock stimulates the expression of Trem–1 on U937 monocytes. Inflamm Res; 58(3): 127–32.

Gibot S, Buonsanti C, Massin F, et al. (2006) Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock. Infect Immun; 74(5): 2823–30.

Bopp C, Hofer S, Bouchon A, et al. (2009) Soluble TREM–1 is not suitable for distinguishing between systemic inflammatory response syndrome and sepsis survivors and nonsurvivors in the early stage of acute inflammation. Eur J Anaesthesiol; 26(6): 504–7.

Kevan EN, Simmons JR, Kocoshis SA, et al. (2011) sTREM–1 and LBP

in central venous catheter-associated bloodstream infections in pediatric

intestinal failure. J Pediatr Gastroenterol Nutr;53(6): 627–33.

Adly AA, Ismail EA, Andrawes NG, El-Saadany MA (2013) Circulating soluble triggering receptor expressed on myeloid cells–1 (sTREM–1) as diagnostic and prognostic marker in neonatal sepsis. Cytokine: S1043-46.

Garofoli F, Borghesi A, Mazzucchelli I, et al. (2010) Preterm newborns are provided with triggering receptor expressed on myeloid cells–1. Int J Immunopathol Pharmacol;23(4): 1297–301.

Sama AE, D'Amore J, Ward MF, et al. (2004) Bench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department. Acad Emerg Med; 11(8): 867–73.

Stros M (2010) HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta; 1799(1–2): 101–13.

Dinarello CA, Gelfand JA, Wolff SM (1993) Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA; 269(14): 1829–35.

Wang H, Bloom O, Zhang M, et al. (1999) HMG–1 as a late mediator of endotoxin lethality in mice. Science; 285(5425): 248–51.

Wang H, Yang H, Czura CJ, et al. (2001) HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med; 164(Pt1): 1768–73.

Ulloa L, Ochani M, Yang H, et al. (2002) Ethyl pyruvate prevents lethality in mice with established lethal seps is and systemic inflammation. Proc Natl Acad Sci USA; 99(19): 12351-6.

Yang H, Ochani M, Li J, et al. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA; 101(1): 296–301.

Pavare J, Grope I, Kalnins I, Gardovska D (2010) High-mobility group box–1 protein, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in children with community acquired infections and bacteraemia: a prospective study. BMC Infect Dis;10:28. doi:10.1186/1471–2334–10–28.

Wong HR, Cvijanovich N, Wheeler DS, et al. (2008) Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med; 178(3): 276-82.


Пристатейна бібліографія ГОСТ






DOI: http://dx.doi.org/10.25284/2519-2078.1(66).2014.85581

Посилання

  • Поки немає зовнішніх посилань.


Creative Commons License
Ця робота ліцензована Creative Commons Attribution-NonCommercial 4.0 International License.

© Асоціація анестезіологів України, 1997-2017. ISSN 2520-226X (Online), ISSN 2519-2078 (Print).

Flag Counter